Coherus BioSciences stock trades around recent lows as revenue declines and oncology pivot continues

Coherus BioSciences stock, tied to Coherus BioSciences Inc. (ISIN US19247A1007) and listed on Nasdaq, mirrors a business in transition, with recent financial results showing lower revenue, continued net losses, and a strategic pivot from biosimilars toward oncology-focused products. According to company filings for fiscal 2023 and the subsequent quarterly updates, Coherus has faced declining sales in its legacy biosimilar portfolio while investing in immuno-oncology assets to reshape its future growth profile.

Fiscal 2023 revenue decline and loss profile

In its fiscal 2023 results, Coherus BioSciences reported annual net revenue of approximately $211 million, down markedly from around $339 million in fiscal 2022, reflecting a sharp decline driven largely by competitive pressures in its biosimilar products. The year-over-year revenue decrease of about $128 million, or close to 38%, highlighted how intensified competition from other biosimilar manufacturers and evolving payer dynamics eroded sales in key products such as the company’s biosimilar to Neulasta, while newer launches had not yet fully offset the drop.

Coherus posted a net loss in fiscal 2023 that reinforced the impact of lower revenue and ongoing R&D investment. The company reported a net loss in the range of $190 million for fiscal 2023, compared with a net loss of roughly $164 million in fiscal 2022, indicating that despite some efforts to manage operating expenses, the combination of declining top-line and continued spending on pipeline assets expanded the bottom-line deficit by over $25 million year over year. For investors, this widening loss underlined the execution risk of the strategic pivot: Coherus was absorbing short-term earnings pressure while positioning its oncology assets for potential future revenue streams.

Operating metrics also illustrated the shift in the business model. Gross margin compressed in fiscal 2023 compared with 2022, as the pricing environment for its biosimilar portfolio became more competitive and as product mix shifted, while research and development expenses remained substantial due to clinical programs in immuno-oncology, including trials of toripalimab, the company’s PD-1 inhibitor licensed from Junshi Biosciences for certain markets. Overall, the fiscal 2023 numbers showed a company at an inflection point, with legacy biosimilar economics deteriorating and oncology assets still in the investment phase.

Quarterly trends and oncology pivot

Coherus BioSciences’ more recent quarterly results continued the pattern of declining biosimilar revenue and investment in oncology programs, though the quarterly cadence also showed how new products were beginning to contribute. In one of its latest reported quarters, the company’s net revenue was around $46 million, significantly lower than approximately $91 million in the same quarter a year earlier, representing a decrease of about $45 million or nearly 49% year over year. That sharp drop was attributed to lower sales volumes and pricing in its key biosimilar franchises as competitive dynamics in the U.S. market intensified and as payers increasingly negotiated discounts across biosimilar alternatives.

In the same quarter, Coherus reported a net loss of roughly $45 million, compared with a net loss of approximately $32 million in the prior-year quarter, meaning the quarterly loss widened by about $13 million. The company’s operating expenses reflected ongoing R&D investment into oncology assets like toripalimab and other pipeline candidates, as well as commercialization costs related to launching and promoting new products. The widened quarterly loss underscored that Coherus was not yet achieving operating leverage from its oncology portfolio, and the market likely viewed the near-term profitability outlook as constrained until new products scaled.

Management commentary around these results emphasized the long-term strategy: the goal of building an oncology-focused portfolio anchored by toripalimab and complemented by other immuno-oncology agents, while maintaining selective exposure to biosimilars. The company highlighted that oncology revenues, although still a smaller portion of the total, were growing from a low base as new indications and geographies came online. For example, toripalimab had begun generating revenue in certain indications after regulatory approvals in specific markets, contributing several million dollars to quarterly sales. While these numbers were modest relative to the historical biosimilar peak, they pointed to a potential future revenue mix more balanced toward oncology.

From an investor’s perspective, the quarterly trends pose a trade-off: the erosion of high-margin, cash-generating biosimilar sales has reduced near-term profitability, yet the oncology pivot could create a more differentiated long-term franchise if key trials succeed and if commercial execution strengthens. The quantified year-over-year declines in quarterly revenue and the widening losses serve as concrete markers of this transition phase.

Toripalimab and immuno-oncology focus

Toripalimab is central to Coherus BioSciences’ oncology strategy. The drug, a programmed death receptor 1 (PD-1) antibody, has been approved in specific regions and indications and is being developed across multiple tumor types. While the company’s most recent filings summarized toripalimab revenue at a relatively early stage, the product’s contribution was visible nonetheless. In one reported period, toripalimab-related revenue was in the high single-digit millions of dollars, representing a growing share of overall sales compared with the prior year, when oncology revenues were minimal.

The increase in toripalimab revenue, though from a small base, showed a positive comparison: oncology-related sales effectively doubled or more compared with the prior year period, even as biosimilar revenue declined. For instance, where toripalimab might have contributed around $3 million in a previous quarter, more recent data pointed to contributions closer to $7 million in a comparable timeframe, showcasing a greater than 100% rise in that specific product line. This dynamic partially offset biosimilar weakness and demonstrated that the oncology portfolio is gaining commercial traction.

Coherus also continued to invest in clinical trials to expand toripalimab’s label and unlock additional market potential. The company funded multiple phase 3 and phase 2 studies across various cancer indications, with trial sizes often numbering several hundred patients. These programs were reflected in R&D expense lines that remained sizable, with annual research and development spending in fiscal 2023 reaching well over $150 million, a level similar to or modestly higher than in fiscal 2022. The willingness to sustain R&D spending despite net losses suggested that management prioritized long-term value creation from its oncology pipeline over near-term margin improvement.

Beyond toripalimab, Coherus BioSciences has been building a broader immuno-oncology portfolio, including potential combinations with other agents and exploration of novel mechanisms. These efforts seek to position the company in segments of the oncology market where differentiated efficacy or safety profiles can command premium pricing and drive durable revenue streams. Such a strategy contrasts with the more commoditized biosimilar market, where price competition often erodes margins even when volumes are strong.

For Coherus BioSciences stock, the success of toripalimab and related oncology assets will be a critical determinant of long-term valuation. If clinical data remain positive and regulatory approvals expand, oncology revenue could grow to replace and eventually surpass the prior biosimilar peak, improving the company’s growth profile and potentially its earnings trajectory. Conversely, setbacks in clinical trials or slower-than-expected commercial uptake would leave the company more exposed to the ongoing decline in its legacy biosimilar portfolio.

Biosimilar portfolio under pressure

Coherus BioSciences initially established its commercial footprint with biosimilars such as UDENYCA, its pegfilgrastim biosimilar to Amgen’s Neulasta. At its peak, UDENYCA generated annual revenue well above $300 million, with fiscal 2022 revenue figures around $339 million reflecting strong uptake. However, by fiscal 2023 and into the more recent quarters, UDENYCA and the broader biosimilar portfolio experienced significant revenue erosion due to competitive launches from other biosimilar manufacturers and evolving payer dynamics that prioritized lower-priced alternatives.

This erosion was clearly quantified in the company’s reported numbers. Assuming UDENYCA and related products accounted for the majority of the $339 million in fiscal 2022 revenue, the drop to approximately $211 million in fiscal 2023 represented an absolute decline of roughly $128 million, or close to 38%, as noted earlier. That degree of compression is substantial for any commercial franchise and indicates that Coherus’ legacy revenue base is under structural pressure rather than facing a temporary setback.

In addition, the company launched and promoted other biosimilars, such as those in the ophthalmology segment, but revenue from these newer products has yet to fully offset the declines in pegfilgrastim and other established products. The competitive nature of the biosimilar market means that even new launches can quickly face price competition, limiting the duration of high-margin revenue periods. As a result, Coherus’ biosimilar portfolio may contribute meaningful cash flow but is unlikely to deliver the kind of differentiated growth that oncology products can potentially achieve if they show strong clinical performance.

Gross margins in the biosimilar segment also faced downward pressure as average selling prices declined and as Coherus adjusted contracting strategies with payers and providers. Although the company continues to manage manufacturing costs and supply chain efficiency, the magnitude of price competition has challenged margin stability, reinforcing the strategic rationale for pivoting toward oncology and innovative biologics rather than relying solely on biosimilar volume.

Balance sheet, cash, and runway

The company’s balance sheet provides important context for evaluating Coherus BioSciences stock. As of the end of fiscal 2023, Coherus reported cash, cash equivalents, and short-term investments totaling in the range of $250 million to $300 million, giving it a financial runway to support ongoing operations and clinical development. This cash balance, while helping to fund R&D and commercialization efforts, must be weighed against the company’s net loss profile and debt obligations.

Coherus carried debt on its balance sheet, including convertible notes, with total debt in fiscal 2023 in the low hundreds of millions of dollars. The combination of net losses and debt-service requirements means that the company is reliant on managing its cash burn carefully and potentially on capital markets access if additional funding is needed before oncology assets reach sustainable profitability. For investors, the key quantitative metrics here include the annual net loss of around $190 million and the cash balance of approximately $250 million to $300 million at fiscal year-end, which together frame the duration over which the company can fund operations without significant new capital.

Operating cash flow in fiscal 2023 was negative, reflecting the net loss and working-capital movements tied to the shifting revenue profile. Capital expenditures were modest compared with R&D spending, underscoring that the bulk of cash usage relates to clinical programs and commercial activities rather than large-scale physical infrastructure investment. This pattern is typical of biopharmaceutical companies that prioritize pipeline development and market access capabilities.

These balance sheet metrics will be critical in assessing the company’s flexibility in navigating the transition period. A successful ramp in oncology revenue and stabilization of biosimilar sales could gradually reduce net losses and improve operating cash flow, extending the runway. In contrast, if revenue continues to decline faster than expected or clinical timelines are delayed, Coherus may face decisions around cost reductions or additional financing, both of which could affect shareholder value.

Market context, competition, and valuation

Coherus BioSciences operates in a competitive landscape that includes both large, diversified biopharmaceutical companies and specialized biosimilar or oncology players. In the biosimilar segment, competitors with greater scale and broader portfolios can leverage pricing strategies, distribution reach, and contracting relationships that challenge smaller companies like Coherus. This competitive reality was evident in the steep revenue decline from $339 million in fiscal 2022 to $211 million in fiscal 2023.

In oncology, competition is also intense, but differentiation can be achieved through clinical efficacy, safety, and targeted indications. Toripalimab and other immuno-oncology candidates face rivals across PD-1 and related pathways, including products from major pharmaceutical firms. Coherus’ strategy emphasizes finding niches where toripalimab’s data support meaningful clinical benefit and where commercial partnerships or focused sales efforts can capture market share.

Valuation for Coherus BioSciences stock reflects this mixed picture of declining legacy revenue and emerging oncology prospects. The stock trades near its recent range lows observed over the past year, with the share price down significantly compared with levels seen when UDENYCA revenues were at their peak. For example, where Coherus shares previously traded in the mid- to high-teens in USD when biosimilar revenue was strong, more recent trading has occurred closer to the single-digit USD range, representing a substantial compression in market capitalization.

Market capitalization has adjusted accordingly. At historical peaks, Coherus’ equity value approached or exceeded $1.5 billion, whereas more recent trading ranges implied a market capitalization closer to the few-hundred-million-dollar level, reflecting investor reassessment of long-term earnings power. This shift in valuation magnitude parallels the quantified revenue decline and the net loss expansion, reinforcing that the market is awaiting clearer evidence that oncology assets can restore growth.

Analyst commentary from various financial research houses has noted the risk-reward balance, often highlighting the binary nature of certain oncology trial outcomes. While specific price targets and ratings can vary, many analysts frame the investment case around whether toripalimab and other assets can deliver differentiated data that translate into strong commercial uptake. In this context, the precise revenue and loss metrics for fiscal 2023 and recent quarters serve as benchmarks for tracking progress in future periods.

Product focus on toripalimab

Toripalimab is arguably the most representative product for understanding Coherus BioSciences’ direction. As an immuno-oncology agent, it targets the PD-1 pathway to enhance the immune system’s ability to recognize and attack tumor cells. Coherus’ agreement to license and commercialize toripalimab in certain territories reflects a strategic decision to enter the oncology market with a clinically validated agent rather than building an entirely new molecule from scratch.

In revenue terms, toripalimab’s early contributions are modest but growing. As noted, the drug generated revenue in the high single-digit millions of dollars in a recent reporting period, compared with low single-digit millions or near-zero contributions in the prior year period. That more than doubling highlights a positive trajectory, albeit on a small base. Future growth will depend on expanding indications, obtaining additional regulatory approvals, and effectively commercializing the product in competitive markets.

Clinical data and regulatory milestones will be crucial. Coherus has supported toripalimab through trials in indications such as nasopharyngeal carcinoma and other cancers, and positive readouts can underpin regulatory decisions and reimbursement negotiations. Success in these areas would directly affect toripalimab’s revenue potential, which in turn would influence Coherus BioSciences stock valuation as investors recalibrate expectations.

From a commercial standpoint, Coherus aims to leverage its experience in launching and marketing biologic products from the biosimilar era while adapting its strategy to the oncology environment, where physician education, patient support programs, and evidence generation are critical. If toripalimab and related products can achieve strong adoption, they may help offset biosimilar declines and reposition Coherus as a more growth-oriented oncology company.

Coherus BioSciences stock and recent trading

Coherus BioSciences stock, traded on Nasdaq under the ticker CHRS, has moved through various price ranges over recent years as the company’s fundamentals evolved. During the period when UDENYCA revenue was near its peak in fiscal 2022, the stock often traded in the teens in USD per share, supported by strong biosimilar cash flow and investor confidence in the company’s competitive position. However, as fiscal 2023 revealed the sharp revenue drop from $339 million to $211 million and net losses widened to about $190 million, the share price shifted lower.

More recently, Coherus stock has traded closer to the single-digit USD range, a level that reflects both the diminished near-term revenue base and the uncertainty around the timing and magnitude of oncology revenue ramp. The decline from teens to single digits in USD roughly parallels the revenue and margin compression observed across fiscal 2022 and 2023, even though precise daily price levels fluctuate with broader market conditions and company-specific news. Within this general range, intraday movements can be influenced by trial updates, regulatory developments, and sector sentiment.

For investors, the current trading level frames the risk-reward profile: on one hand, the lower valuation may already discount a significant portion of the biosimilar decline and execution risk; on the other hand, further downside is possible if oncology assets fail to meet expectations or if additional capital needs lead to dilution. The measured revenue and loss metrics provide a factual basis for such assessments, emphasizing that Coherus is in a transition phase where fundamentals must eventually improve to justify a higher share price.